CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the Lineage Third Quarter 2024 Earnings Conference Call. All lines have been placed on ...
Lineage Cell Therapeutics, Inc. ( (LCTX)) has released its Q3 earnings. Here is a breakdown of the information Lineage Cell Therapeutics, Inc. presented to its investors. Lineage Cell Therapeutics, ...
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were ...
* For purposes of section 897(h)(1) of the Internal Revenue Code, the Company is disclosing the return of capital distribution includes $0.0003 per share of section 897 look-through distribution gain.
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback